{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"44"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"41"}]}],"title":"Any Treatment-Related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"20"}]}],"title":"Any Treatment-Emergent SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"7"}]}],"title":"Any Treatment-Related Treatment-Emergent SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"2"}]}],"title":"Any TEAE Leading to Discontinuation of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"44"}],"units":"Participants"}],"description":"Treatment Emergent Adverse Events (TEAEs) are those that first occur or increase in severity on or after the first dose and not more than 28 days after the last dose, and prior to the initiation of subsequent systemic anti-cancer therapy. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"},{"description":"Eligible participants receiving Docetaxel earlier in the study switched to Adagrasib based on physician decision. Participants were administered with Adagrasib orally at a starting dose of 600 mg twice a day (BID).","id":"OG002","title":"Crossover Adagrasib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population included all the participants who received at least one dose of the study drug. Docetaxel arm do not include adverse events after initiation of crossover Adagrasib treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}